NASDAQ:NTGN - Neon Therapeutics Stock Price, News, & Analysis Sign in or create an account to add this stock to your watchlist. Get Started $5.50 -0.13 (-2.31 %) (As of 03/22/2019 06:37 AM ET)Previous Close$5.63Today's Range$5.39 - $5.6352-Week Range$4.20 - $16.23Volume109,304 shsAverage Volume191,545 shsMarket Capitalization$155.82 millionP/E Ratio-0.99Dividend YieldN/ABetaN/A ProfileDiscussionAnalyst RatingsChartEarningsInsider TradesInstitutional OwnershipHeadlinesSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Neon Therapeutics, Inc., a clinical-stage immuno-oncology company, engages in developing neoantigen-targeted therapies for cancers in the United States. It is developing NEO-PV-01, a neoantigen vaccine that is in Phase Ib clinical trial in combination with nivolumab for the treatment of metastatic melanoma, non-small cell lung cancer, and bladder cancer; NEO-PTC-01, a neoantigen T cell therapy for the treatment of solid tumors; and NEO-SV-01, a neoantigen vaccine for the treatment of estrogen-receptor-positive breast cancer. Neon Therapeutics, Inc. has a clinical trial collaboration with Natera, Inc. to assess the treatment response to personal cancer vaccine. The company was founded in 2013 and is headquartered in Cambridge, Massachusetts. Receive NTGN News and Ratings via Email Sign-up to receive the latest news and ratings for NTGN and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange NASDAQ Industry Biological products, except diagnostic Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:NTGN Previous Symbol CUSIPN/A CIKN/A Webwww.neontherapeutics.com Phone617-337-4701Debt Debt-to-Equity RatioN/A Current Ratio8.31 Quick Ratio8.31Price-To-Earnings Trailing P/E Ratio-0.99 Forward P/E Ratio-2.01 P/E GrowthN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$3.58 per share Price / Book1.54Profitability EPS (Most Recent Fiscal Year)($5.54) Net Income$-76,930,000.00 Net MarginsN/A Return on Equity-122.27% Return on Assets-65.61%Miscellaneous EmployeesN/A Outstanding Shares28,330,000Market Cap$155.82 million Next Earnings Date6/10/2019 (Estimated) OptionableNot Optionable Neon Therapeutics (NASDAQ:NTGN) Frequently Asked Questions What is Neon Therapeutics' stock symbol? Neon Therapeutics trades on the NASDAQ under the ticker symbol "NTGN." How were Neon Therapeutics' earnings last quarter? Neon Therapeutics Inc (NASDAQ:NTGN) issued its quarterly earnings results on Monday, March, 11th. The company reported ($0.84) EPS for the quarter, missing the Thomson Reuters' consensus estimate of ($0.73) by $0.11. View Neon Therapeutics' Earnings History. When is Neon Therapeutics' next earnings date? Neon Therapeutics is scheduled to release their next quarterly earnings announcement on Monday, June 10th 2019. View Earnings Estimates for Neon Therapeutics. What price target have analysts set for NTGN? 3 brokerages have issued 12 month price objectives for Neon Therapeutics' shares. Their predictions range from $18.00 to $23.00. On average, they expect Neon Therapeutics' stock price to reach $20.25 in the next twelve months. This suggests a possible upside of 268.2% from the stock's current price. View Analyst Price Targets for Neon Therapeutics. What is the consensus analysts' recommendation for Neon Therapeutics? 3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Neon Therapeutics in the last year. There are currently 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Neon Therapeutics. Has Neon Therapeutics been receiving favorable news coverage? News stories about NTGN stock have trended somewhat positive on Friday, InfoTrie Sentiment Analysis reports. The research firm identifies positive and negative media coverage by monitoring more than six thousand news and blog sources. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Neon Therapeutics earned a daily sentiment score of 1.7 on InfoTrie's scale. They also gave media coverage about the company a news buzz of 2.0 out of 10, indicating that recent media coverage is very unlikely to have an impact on the company's share price in the near term. Who are some of Neon Therapeutics' key competitors? Some companies that are related to Neon Therapeutics include Twist Bioscience (TWST), Voyager Therapeutics (VYGR), MeiraGTx (MGTX), Scholar Rock (SRRK), DBV TECHNOLOGIE/S (DBVT), PDL BioPharma (PDLI), Translate Bio (TBIO), Mesoblast (MESO), Replimune Group (REPL), Avrobio (AVRO), Adaptimmune Therapeutics (ADAP), Agenus (AGEN), Solid Biosciences (SLDB), Adverum Biotechnologies (ADVM) and Gritstone Oncology (GRTS). What other stocks do shareholders of Neon Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Neon Therapeutics investors own include Altria Group (MO), Cisco Systems (CSCO), Thermo Fisher Scientific (TMO), Alibaba Group (BABA), Honeywell International (HON), Home Depot (HD), Johnson & Johnson (JNJ), Raytheon (RTN), Mcdonald's (MCD) and United Technologies (UTX). Who are Neon Therapeutics' key executives? Neon Therapeutics' management team includes the folowing people: Mr. Hugh O'Dowd, Pres, CEO & Director (Age 54)Dr. Eric S. Lander, Founder & Director (Age 62)Dr. Yasir B. Al-Wakeel, Chief Financial Officer (Age 37)Dr. Richard Gaynor, Pres of R&D (Age 69)Dr. Edward Fritsch Ph.D., Founder and Chief Technology Officer When did Neon Therapeutics IPO? (NTGN) raised $101 million in an IPO on Wednesday, June 27th 2018. The company issued 6,300,000 shares at $15.00-$17.00 per share. Morgan Stanley, BofA Merrill Lynch and Mizuho Securities acted as the underwriters for the IPO and Oppenheimer was co-manager. Who are Neon Therapeutics' major shareholders? Neon Therapeutics' stock is owned by a variety of of retail and institutional investors. Top institutional investors include FMR LLC (7.35%), Hillhouse Capital Management Ltd. (1.41%), Hillhouse Capital Advisors Ltd. (1.10%), BlackRock Inc. (1.09%), Casdin Capital LLC (0.93%) and Northern Trust Corp (0.31%). View Institutional Ownership Trends for Neon Therapeutics. Which major investors are selling Neon Therapeutics stock? NTGN stock was sold by a variety of institutional investors in the last quarter, including Hillhouse Capital Management Ltd. and Casdin Capital LLC. View Insider Buying and Selling for Neon Therapeutics. Which major investors are buying Neon Therapeutics stock? NTGN stock was purchased by a variety of institutional investors in the last quarter, including Hillhouse Capital Advisors Ltd., Northern Trust Corp, Geode Capital Management LLC, Geode Capital Management LLC, BlackRock Inc., FMR LLC, Bank of America Corp DE and Bank of New York Mellon Corp. View Insider Buying and Selling for Neon Therapeutics. How do I buy shares of Neon Therapeutics? Shares of NTGN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab. What is Neon Therapeutics' stock price today? One share of NTGN stock can currently be purchased for approximately $5.50. How big of a company is Neon Therapeutics? Neon Therapeutics has a market capitalization of $155.82 million. The company earns $-76,930,000.00 in net income (profit) each year or ($5.54) on an earnings per share basis. What is Neon Therapeutics' official website? The official website for Neon Therapeutics is http://www.neontherapeutics.com. How can I contact Neon Therapeutics? Neon Therapeutics' mailing address is 40 ERIE STREET SUITE 110, CAMBRIDGE MA, 02139. The company can be reached via phone at 617-337-4701 or via email at [email protected] MarketBeat Community Rating for Neon Therapeutics (NASDAQ NTGN)Community Ranking: 2.4 out of 5 ( )Outperform Votes: 63 (Vote Outperform)Underperform Votes: 69 (Vote Underperform)Total Votes: 132MarketBeat's community ratings are surveys of what our community members think about Neon Therapeutics and other stocks. Vote "Outperform" if you believe NTGN will outperform the S&P 500 over the long term. Vote "Underperform" if you believe NTGN will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 3/22/2019 by MarketBeat.com StaffFeatured Article: Why do companies engage in swaps?